NASDAQ:ACGN Aceragen (ACGN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.38▼$0.3850-Day Range$0.38▼$0.9052-Week Range$0.36▼$16.00VolumeN/AAverage VolumeN/AMarket Capitalization$3.20 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Aceragen alerts: Email Address Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. About Aceragen Stock (NASDAQ:ACGN)Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. and changed its name to Aceragen, Inc. in January 2023. Aceragen, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.Read More Ad Porter & CompanyWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. ACGN Stock News HeadlinesAugust 26, 2023 | ca.finance.yahoo.comACGN - Aceragen, Inc.August 8, 2023 | msn.comU.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.16%September 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 4, 2023 | finance.yahoo.comAceragen, Inc. to Delist from The Nasdaq Stock MarketJuly 12, 2023 | bizjournals.comCash-strapped public company in Durham moves to liquidate. Will shareholders get anything?July 11, 2023 | bizjournals.comInvestor wants its money back as Durham firm weighs bankruptcyJune 29, 2023 | chron.comAceragen: Q1 Earnings SnapshotMay 30, 2023 | finance.yahoo.comAceragen, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-Q FilingSeptember 16, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.April 17, 2023 | bizjournals.comDurham public company begins furloughs as it searches for capitalMarch 30, 2023 | benzinga.comAceragen Stock (NASDAQ:ACGN), Guidance and ForecastMarch 5, 2023 | barrons.comAceragen Inc.March 1, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Aceragen (ACGN)February 6, 2023 | finance.yahoo.comAceragen Announces Recommendation of Data Monitoring Committee in Terra StudySee More Headlines Receive ACGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aceragen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:ACGN CUSIPN/A CIK861838 Webwww.iderapharma.com Phone(484) 348-1600Fax617-679-5592Employees26Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$4.86 million Price / Sales0.66 Cash FlowN/A Price / Cash FlowN/A Book Value$3.24 per share Price / Book0.12Miscellaneous Outstanding Shares8,420,000Free Float6,196,000Market Cap$3.20 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. John C. Taylor (Age 52)Pres, CEO & Director Comp: $444.06kMs. Gwen ThomasAssociate Director of HR, Fin. & Admin.Ms. Christina AmendolaDirector of HRMr. Brian JackeySr. VP of Technical OperationsMs. Deepa NagpalGlobal Head of QualityDr. Shah Rahimian M.D.Ph.D., Medical Director & Global Clinical Lead for OncologyDr. Joanna Caroline Horobin Ch.B (Age 68)M.B., Advisor Mr. Louis J. Arcudi III (Age 62)M.B.A., MBA, Adviser More ExecutivesKey CompetitorsAyala PharmaceuticalsNASDAQ:AYLAInhibikase TherapeuticsNYSE:IKTOrganovoNASDAQ:ONVOCoeptis TherapeuticsNASDAQ:COEPAptose BiosciencesNASDAQ:APTOView All Competitors This page (NASDAQ:ACGN) was last updated on 9/16/2024 by MarketBeat.com Staff From Our Partners44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aceragen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aceragen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.